



Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference

April 8, 2024

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Apr. 8, 2024-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer will participate in a panel at the Canaccord Genuity Horizons in Oncology Virtual Conference being held April 15, 2024.

Details of the event are as follows:

Panel: "Off-the-Shelf CART – Let's Talk Lupus and Oncology"

Date: Monday, April 15, 2024

Time: 3:00 p.m. ET

The Adicet Bio team will be available for one-on-one meetings throughout the conference. Please contact your sales representative at Canaccord Genuity to register for a meeting with the company.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at <https://www.adicetbio.com>.

View source version on [businesswire.com](https://www.businesswire.com): <https://www.businesswire.com/news/home/20240408693156/en/>

Adicet Bio., Inc.

Investor and Media Contacts

Anne Bowdidge

abowdidge@adicetbio.com

Janhavi Mohite

Stern Investor Relations, Inc.

212-362-1200

janhavi.mohite@sternir.com

Source: Adicet Bio, Inc.